Vlad Matei, MD
Retina Specialist · Boulder, CONPI 1922397819
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Carl Zeiss Meditec, Inc. at 45.5% of the total. Reporting peaked in 2022 at $6,042 and has fallen 80.5% since, to $1,178 in 2025.
Across 121 payments — averaging $101.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$6K
- AbbVie$1K
- Regeneron$997
- Regeneron Healthcare Solutions, Inc.$848
- Genentech, Inc.$806
- Alimera Sciences, Inc.$569
- plus $2K from 15 others
What the payments were for
- Consulting fees$9898%
- Speaking & faculty fees$5,50045%
- Travel & lodging$9978%
- Food & beverage$4,65338%
- Entertainment$921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 3 | $5,570 |
| AbbVie(2 entities) | 11 | $1,312 |
| Regeneron | 2 | $997 |
| Regeneron Healthcare Solutions, Inc. | 22 | $848 |
| Genentech, Inc. | 5 | $806 |
| Alimera Sciences, Inc. | 18 | $569 |
| Astellas Pharma US Inc | 11 | $492 |
| Genentech USA, Inc. | 11 | $368 |
| Apellis Pharmaceuticals, Inc. | 4 | $189 |
| Astellas Pharma Global Development | 1 | $164 |
| Alcon | 3 | $148 |
| Eyepoint US, Inc. | 2 | $138 |
| Bausch & Lomb Americas Inc. | 5 | $113 |
| Optos, Inc. | 2 | $105 |
| Biogen | 5 | $96 |
| Harrow Eye, LLC | 4 | $79 |
| ANI Pharmaceuticals, Inc. | 4 | $73 |
| Coherus Oncology, Inc. | 4 | $68 |
| Amgen | 1 | $39 |
| Akorn, Inc. | 2 | $33 |
| Novartis | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CLARUS$4,400
- FORUM$4,400
- FORUM Glaucoma Workplace$4,400
- Humphrey HFA$4,400
- OZURDEX$1,106
- CIRRUS HD-OCT$1,100
- VABYSMO$533
- Izervay$449
- EYLEA$362
- SUSVIMO$258
- Iluvien$256
- Lucentis$131
- YUTIQ$116
- Syfovre$114
How this compares
$12,231 in reported general payments places this provider in the 70th percentile of 51 retina specialist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Difluprednate | 50 | $5,083 |
| Prednisolone Acetate | 67 | $2,864 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 21 | $2,575 |
| Atropine Sulfate | 19 | $833 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 63 | $785 |
| Ketorolac Tromethamine | 21 | $614 |
| Latanoprost | 45 | $352 |
| Dorzolamide Hcl | 13 | $283 |
| Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate | 14 | $208 |
| Timolol Maleate | 21 | $145 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 13 | $89 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Boulder
- Brent DeibertBoulder$9K
- Murtaza AdamParker$548K
- Alan KimuraDenver$546K
- Brian JoondephDenver$92K
- Talisa ForestAurora$84K
- Sara HaugDurango$59K
- Matthew ManryLongmont$43K
- Ashleigh LevisonLafayette$33K
- Mimi LiuEnglewood$23K
- Moss FenbergDurango$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.